Calidi Biotherapeutics, Inc.

Calidi Biotherapeutics, Inc. is a clinical-stage immuno-oncology company dedicated to developing targeted genetic medicines and oncolytic virotherapies to combat cancer. The company's core mission revolves around pioneering therapies that arm the immune system to effectively fight cancer by delivering genetic medicines to tumor sites. Headquartered in San Diego, California, Calidi Biotherapeutics was founded in 2014.

Calidi Biotherapeutics' pipeline features several proprietary platforms designed to protect, amplify, and potentiate oncolytic viruses for enhanced efficacy and patient safety. Key platforms include RedTail, a systemic delivery platform utilizing an engineered enveloped oncolytic virus for metastatic cancers; NeuroNova, which employs allogeneic neural stem cells loaded with an oncolytic adenovirus for high-grade gliomas; and SuperNova, using allogeneic adipose-derived mesenchymal stem cells with an oncolytic vaccinia virus for solid tumors. Lead product candidates include CLD-401 (from the RedTail platform, an IL-15 superagonist for solid tumors), CLD-101 (NeuroNova for high-grade gliomas), and CLD-201 (SuperNova for advanced metastatic solid tumors like TNBC, SCCHN, and Sarcoma).

Recent notable developments for Calidi Biotherapeutics include a public offering in March 2026 and a partnership with Avance Clinical to facilitate Australian regulatory approval and accelerate clinical trials for CLD-401. The company has also presented new data on its RedTail platform and CLD-401 at the AACR Annual Meeting in April 2026 and partnered with TransferAI to leverage AI in the IND submission process for CLD-401. Dr. Eric Poma serves as the Chief Executive Officer and Director, having been appointed in May 2025, succeeding Allan Camaisa, who is now CEO Emeritus and Director. Calidi Biotherapeutics became a publicly traded company in September 2023 through a merger with a special purpose acquisition company (SPAC).